Reneo Pharmaceuticals announced that it has commenced an underwritten public offering of its shares of common stock. Jefferies, BofA Securities, and Piper Sandler are acting as joint book-running managers and Robert W. Baird & Co. is acting as a lead manager for the underwritten public offering.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPHM:
- Reneo Announces Pricing of Public Offering of Common Stock
- Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Reneo Pharmaceuticals reports Q4 EPS (56c), consensus (60c)
- Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies
